董事会谨此重申，集团将继续专注于主营网约车业务，持续提升运营效率及服务质量，并在审慎塬则下 推进包括自动驾驶及国际化拓展在内的中长期战略布局。公司管理层对集团的长期发展前景保持审慎而 积极的态度。 智通财经APP讯，曹操出行(02643)公布，董事会注意到公司股份价格及成交量近期出现不寻常变动。经 作出合理查询后，董事会确认，截至本公告日期，其并不知悉任何导致该等股价及成交量变动的原因， 或任何必须披露以避免公司证券出现虚假市场的资料或任何须根据香港法例第571章证券及期货条例第 XIVA部予以披露的内幕消息。 目前，集团业务营运正常，整体业务基本面未发生任何重大不利变化。 核心网约车业务保持稳健发展，经营情况符合管理层预期;同时，集团在自动驾驶 (Robotaxi)领域的中长 期战略方向清晰，并按既定规划稳步推进。与此同时，集团正稳步加强国际化业务布局，积极探索海外 市场及相关合作机会，以支持公司中长期发展战略。 ...

本报记者 王宁 业内人士表示，南华期货有望成为期货业第二家"A+H"期货公司。一方面，境外业务已成为该公司重要的业绩增长引擎， 通过联交所上市可有效补充其境外子公司资本金，进一步扩大境外业务规模、优化业务结构，提升国际市场竞争力与抗风险能 力；另一方面，中国香港作为国际金融枢纽，能为该公司开辟多元融资渠道，吸引全球资本，更好服务中资企业"出海"的跨境 风险管理需求。 上述受访业内人士向记者表示，南华期货通过A股上市，资本金获得明显补充，为公司发展提供了多维度支撑。从经营层 面来看，上市拓宽了融资渠道，为公司业务拓展与技术投入奠定基础；从业务布局来看，上市融资给了该公司推进业务多元化 的底气，使其构建起涵盖境内外期货经纪、风险管理、境外金融服务的综合业务体系；从公司治理与合规来看，上市后需满足 更高信息披露与监管要求，该公司通过完善治理架构，强化内部控制与风险管理，持续提升运营规范性与透明度，增强投资者 与客户信任度，为业务长期稳健发展提供保障。 综合来看，上市为期货公司带来资金、品牌和治理规范等多方面的优势，并进一步助力其业务布局呈现多元化、全球化拓 展特征。 安粮期货常务副总经理、董事会秘书余萍向《证券日报 ...

格隆汇12月2日｜曼卡龙公告，公司于2025年12月2日召开了第六届董事会第七次会议，审议通过了《关 于对外投资设立香港全资子公司的议案》，同意公司在中国香港投资设立全资子公司香港智合实业有限 公司，香港智合注册资本为1万美元，公司持有其100%股权。本次对外投资总额不超过350万美元，实 际投资金额以主管部门的审批金额为准，资金来源为公司自有资金。本次对外投资设立香港全资子公 司，是基于公司战略发展及国际化业务布局需要所作出的决策，对公司长期发展具有积极影响。 ...

Core Viewpoint - The Hong Kong stock market is experiencing a decline, but Yao Cai Securities has seen a significant increase in its stock price due to the approval of Ant Group's acquisition by the Hong Kong Securities and Futures Commission [2][3]. Group 1: Market Performance - The Hong Kong stock market is overall down, with the three major indices showing a decline [2]. - Yao Cai Securities' stock price surged by over 30%, reaching a peak increase of 37.39% during the trading session [2]. Group 2: Acquisition Details - Ant Group's acquisition of Yao Cai Securities has received approval from the Hong Kong Securities and Futures Commission, but it still requires approval from the National Development and Reform Commission [2]. - On October 10, Yao Cai Securities announced that the offeror has been approved to become a major shareholder of regulated group companies, which include Yao Cai Futures and Yao Cai Asset Management [2]. - The approval from the Securities and Futures Commission is valid for six months or a longer period if agreed upon in writing [2]. Group 3: Financial Aspects - Ant Group, through its wholly-owned subsidiary Shanghai Yun Jin, has made an offer to acquire Yao Cai Securities at a price of HKD 3.28 per share, totaling HKD 28.14 billion [3]. - This acquisition price represents a 7.5% premium over the closing price before the suspension of trading and a 365% premium over the book value per share disclosed in the mid-2025 financial report [3]. - Yao Cai Securities holds various financial service licenses, and the acquisition will allow Ant Group to enhance its service offerings in the securities sector [3].

Group 1 - The core viewpoint of the article highlights the ongoing efforts of Tianrong Tianyu to enhance its international business layout and capitalize on global integration opportunities, particularly in Southeast Asia [1] - In the first half of 2025, the company's factories in Thailand and India generated a revenue of 73.6632 million yuan, representing an increase of 11.74% compared to the same period last year [1] - The foreign sales revenue, including exports and income from overseas factories, reached 207 million yuan, marking a growth of 16.13% year-on-year [1] Group 2 - The production and operational conditions at the company's Southeast Asia production base are reported to be good, with a high capacity utilization rate and sufficient orders [1] - The growth in local customer orders is expected to further enhance the company's overall operational performance [1]

Core Viewpoint - The company reported significant revenue growth and advancements in its product pipeline for the treatment of structural heart diseases, indicating a strong foundation for future growth [1]. Financial Performance - The company achieved revenue of 13.426 million RMB for the six months ending June 30, 2025, compared to no revenue in the same period last year [1]. - Gross profit reached 11.827 million RMB, also showing an increase from zero in the previous year [1]. - Research and development expenses amounted to 88.885 million RMB [1]. Product Development - The company made substantial progress in its product pipeline for treating tricuspid, aortic, and mitral valve diseases, resulting in a diversified and high-potential product portfolio [1]. - The commercialization of interventional products for treating structural heart diseases has been a key driver of revenue growth [1]. Strategic Initiatives - The company is intensifying its international business expansion efforts to enhance product influence and clinical application scale, laying a solid foundation for long-term high-speed growth [1].

Group 1 - The company reported a revenue of 1.335 billion yuan for 2024, with design revenue at 780 million yuan, EPC revenue at 208 million yuan, and supervision and project management revenue at 244 million yuan. The net profit attributable to shareholders was 51.3174 million yuan, and after excluding goodwill impairment of 60.5721 million yuan, the net profit was 112 million yuan [1] - The company aims to focus on strategic leadership, business expansion, and risk prevention while actively exploring market opportunities and international business layouts to enhance management efficiency and support the construction of new productive forces [1] Group 2 - The company has played a significant role in the development of high-quality modern industrial buildings in Suzhou Industrial Park, contributing to the growth of various industries, particularly in innovative pharmaceuticals and high-end medical devices [2] - The company has successfully completed numerous new productive force projects across multiple cities, including the Yangtze River Delta Kunshan International Low Carbon Innovation Park and the Huazhong Intelligent Aircraft Industry Base [3] - The company has achieved notable success in the aerospace manufacturing sector, winning bids for several high-end manufacturing bases, including projects for Tianbing Technology and Shandong Jianyuan Aerospace Technology [3] Group 3 - The company has been actively expanding its international presence, winning major design projects in Indonesia and Peru, and establishing subsidiaries in Malaysia and Singapore to enhance its competitiveness in the Middle East [4] - The company has undertaken over 20 projects overseas, including in Southeast Asia and regions like Kenya and Serbia, focusing on industrial park and economic zone planning and design [4][5] - The international expansion has not only strengthened the company's market competitiveness but also provided new growth points for its global business development [5]